Atyr Pharma, Inc.
A San Diego biotech developing medicines from tRNA synthetases, the enzymes best known for building proteins inside cells. Its lead drug candidate, efzofitimod, targets fibrosis and inflammation, such as scarring of the lungs. Founded in 2005 by scientists Paul Schimmel and Xiang-Lei Yang, it grew out of their discovery that these enzymes also act outside cells as signaling molecules — a twist that gives the company its name, taken from tyrosyl-tRNA synthetase.
Granted 1.85M · Bought 2.92M · Sold 8.4K
Bought 320.0K
Bought 320.0K
Bought 359.4K
Bought 50.0K
Granted 45.1K · Bought 113.5K · Sold 5.3K
Granted 6.0K · Bought 50.0K
Granted 16.8K · Bought 98.8K · Sold 6.7K
Granted 11.6K · Bought 5.0K · Sold 2.3K
Granted 6.7K · Bought 11.0K · Sold 1.4K
Granted 12.5K · Sold 4.7K
Granted 6.0K · Sold 17.5K
Bought 12.4K
Granted 6.0K · Bought 3.8K
Granted 6.0K
Granted 6.0K
Granted 3.3K · Sold 1.4K
Bought 29.6K · Sold 3.22M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schimmel PaulDirector · 44 transactions | — | 3.62M | 1.85M | 2.92M | 8.4K |
| Nashat AmirReporting owner · 8 transactions | — | 1.84Mas of May 2015 | — | — | — |
| Blair James C +6 co-filersDirector, 10% owner, 10% owner · 1 transaction | — | 1.81Mas of May 2015 | — | — | — |
| CHP II LP +3 co-filers10% owner · 1 transaction | — | 1.76Mas of May 2015 | — | — | — |
| Polaris Venture Management Co. V, L.L.C. +4 co-filers10% owner · 8 transactions | — | 1.74Mas of May 2015 | — | — | — |
| Champsi Farah +4 co-filers10% owner · 2 transactions | — | 1.69Mas of May 2015 | — | — | — |
| Akkaraju SrinivasReporting owner · 2 transactions | — | 1.55Mas of May 2015 | — | 320.0K | — |
| Healy James +4 co-filers10% owner · 2 transactions | — | 1.55Mas of May 2015 | — | 320.0K | — |
| Mendlein JohnDirector · 10 transactions | — | 615.4Kas of Dec 2018 | — | 359.4K | — |
| Deerfield Management Co +5 co-filersReporting owner · 4 transactions | — | 486.5Kas of May 2015 | — | 50.0K | — |
| Shukla SanjayPresident and CEO, Director · 21 transactions | — | 153.6K | 45.1K | 113.5K | 5.3K |
| Coughlin TimothyDirector · 4 transactions | — | 56.0Kas of May 2024 | 6.0K | 50.0K | — |
| Broadfoot Jill MarieChief Financial Officer · 18 transactions | — | 37.3K | 16.8K | 98.8K | 6.7K |
| Denyes NancyGeneral Counsel · 9 transactions | — | 33.1K | 11.6K | 5.0K | 2.3K |
| Amanullah AshrafSee Remarks · 4 transactions | — | 26.3Kas of May 2018 | 6.7K | 11.0K | 1.4K |
| Krueger NancyGeneral Counsel · 2 transactions | — | 25.3Kas of May 2019 | 12.5K | — | 4.7K |
| Clarke John KDirector · 8 transactions | — | 19.8Kas of Apr 2023 | 6.0K | — | 17.5K |
| Blair James C +6 co-filersDirector, 10% owner, 10% owner · 1 transaction | — | 13.4Kas of May 2015 | — | — | — |
| Matsuoka GroveSee Remarks · 2 transactions | — | 12.4Kas of May 2016 | — | 12.4K | — |
| Gross Jane ADirector · 2 transactions | — | 9.8Kas of Mar 2025 | 6.0K | 3.8K | — |
| Lucas SvetlanaDirector · 1 transaction | — | 6.0Kas of Apr 2023 | 6.0K | — | — |
| Zaknoen SaraDirector · 1 transaction | — | 6.0Kas of Apr 2023 | 6.0K | — | — |
| Blake John TSenior Vice President, Finance · 2 transactions | — | 1.9Kas of Feb 2018 | 3.3K | — | 1.4K |
| EcoR1 Capital Fund Qualified, L.P.10% owner · 9 transactions | — | 0as of May 2018 | — | 29.6K | 3.22M |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +1.02M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.